-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KUYGtvB8+VMVnjiBV0zbcojQgyz/Y32RdWVoNR0UH6OK+BdBwJkNbJXruYawR55l 06EIW7eXqO/6Z2oLxC5aJA== 0001354457-09-000038.txt : 20090217 0001354457-09-000038.hdr.sgml : 20090216 20090217103937 ACCESSION NUMBER: 0001354457-09-000038 CONFORMED SUBMISSION TYPE: 25-NSE CONFIRMING COPY: PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20090217 DATE AS OF CHANGE: 20090217 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INTROGEN THERAPEUTICS INC CENTRAL INDEX KEY: 0001018710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 742704230 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25-NSE SEC ACT: 1934 Act SEC FILE NUMBER: 000-21291 BUSINESS ADDRESS: STREET 1: 301 CONGRESS AVE STREET 2: SUITE 1850 CITY: AUSTIN STATE: TX ZIP: 78701 BUSINESS PHONE: 5127089310 MAIL ADDRESS: STREET 1: 301 CONGRESS AVE STREET 2: SUITE 1850 CITY: AUSTIN STATE: TX ZIP: 78701 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NASDAQ Stock Market LLC CENTRAL INDEX KEY: 0001354457 IRS NUMBER: 521165937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25-NSE BUSINESS ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-978-4144 MAIL ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 25-NSE 1 primary_doc.xml X0203 0001354457 NASDAQ Stock Market LLC 0001018710 INTROGEN THERAPEUTICS INC 000-21291
2250 Holcombe Boulevard, Suite 1850 Houston TX TEXAS 77030
512-708-9310 Common stock 17 CFR 240.12d2-2(b) Amy Horton Associate General Counsel 2009-02-17 EX-99.25 2 ingndelistreason.txt Delisting Determination,The Nasdaq Stock Market, LLC, February 17, 2009, Introgen Therapeutics, Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock of Introgen Therapeudics, Inc. (the Company), effective at the opening of the trading session on February 27, 2009. Based on a review of the information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Marketplace Rule 4450(b)(01). The Company was notified of the Staffs determination on September 4, 2008. The Company requested a review of the Staffs determination before the Listing Qualifications Hearings Panel. Upon review of the information provided by the Company, the Panel transferred the Company's securities to the Nasdaq Capital Market conditioned upon the Company's showing compliance with Marketplace Rule 4310(c)(02) by March 3, 2009. ON December 4, 2008, the Company notified the Panel that it had filed for bankruptcy protection under Chapter 11 of the U.S. Bankruptcy Code and would be unable to reestablish compliance with the Nasdaq listing standards. On December 5, 2008, the Panel notified the Company that it had determined to delist the Company's securities and that trading in the Companys securities would suspended on December 5, 2008. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on January 20, 2009. -----END PRIVACY-ENHANCED MESSAGE-----